Donepezil, galantamine, rivastigmine and memantine for the treatment of Alzheimer's disease (Review of TA 111)
ثبت نشده
چکیده
Alzheimer’s disease is a serious progressive neurodegenerative disorder with devastating consequences for the patient. Donepezil has a significant body of clinical evidence, previously accepted by NICE and restated in the Eisai/Pfizer submission, that demonstrates the efficacy of donepezil in the symptomatic management of both mild and moderate AD. This evidence base shows that donepezil delays symptomatic deterioration in a number of aspects of the disease, including cognition, behavioural symptoms and function, and that cessation of therapy results in a rapid loss of these benefits.
منابع مشابه
The Effects of Donepezil, Galantamine, Rivastigmine and Memantine on Mini-Mental State Examination and Mean Flow Velocity in Patients with Vascular Dementia: A Double-Blinded Randomized Clinical Trial
Background: Vascular dementia is one of the most common forms of dementia. At now, there is no treatment available to cure vascular dementia or to alter its clinical course. Some studies suggest that some drugs may be useful in controlling symptoms. The aim of this study was to evaluate the effects of donepezil, memantine, rivastigmine and galantamine on mean flow velocity and ...
متن کاملSubmission on Behalf of the British Geriatrics Society to the National Institute for Clinical Excellence Health Technology Appraisal: Donepezil, Galantamine, Rivastigmine and Memantine for the Treatment of Alzheimer’s Disease
Alzheimer’s disease (AD) is the most common cause of dementia and is a progressive neurodegenerative illness for which at present there is no cure. The management involves both nonpharmacological and pharmacological approaches. This submission will concentrate mostly on the acetylcholinesterase inhibitors (AChEI), donepezil, rivastigmine and galantamine as well as the NMDA receptor antagonist m...
متن کاملTwo cases of Alzheimer’s disease showing deterioration of behavioral and psychological symptoms of dementia induced by switching from rivastigmine to donepezil
Rivastigmine, galantamine, and memantine, in addition to donepezil, which has been on the market over 10 years, have been available for the treatment of Alzheimer's disease (AD) since 2011 in Japan, leading a new stage in the medical treatment of AD. We studied two AD patients showing sudden deterioration of behavioral and psychological symptoms of dementia (BPSD) associated with switching from...
متن کاملCurrent treatments of Alzheimer disease: are main caregivers satisfied with the drug treatments received by their patients?
BACKGROUND/AIMS A full comparison of the satisfaction with treatment using the current Alzheimer's disease (AD) therapies from the perspective of caregivers has not yet been done. The aim of this study was thus to find out the degree of satisfaction with the main available drug treatments in monotherapy for AD from this point of view. METHODS A cross-sectional, multicentre study of patients w...
متن کامل